PT-141 10mg

Bremelanotide (or PT-141) is a compound developed for the treatment of female sexual dysfunction, hemorrhagic shock, and reperfusion injury. It works by activating the melanocortin receptors MC1R and MC4R, modulating inflammation and limiting ischemia.  Initially, the drug was studied for intranasal use to treat female sexual dysfunction, but in 2008, development of the drug for such use was temporarily halted after reports of adverse side effects associated with increased blood pressure. In March 2012 Palatin Technologies was conducting a Phase 2B study in humans using subcutaneous injection of the drug, which the manufacturer says will have a very small effect on blood pressure.

Bremelanotide was developed from the peptide hormone Melanotan 2, which was studied as a tanning agent without sun exposure. In initial tests, Melanotan 2 was shown to induce sexual arousal and spontaneous erections in addition to tanning.  Bremelanotide has been shown to be effective in studies in treating sexual dysfunction in both men (erectile dysfunction) and women (sexual arousal disorder). Unlike Viagra and other related drugs, Bremelanotide has no effects on the vascular system, but increases desire directly through its action. effect on the nervous system.

Purpose of use

Used in male or female sexual dysfunction

Mechanism of action

Bremelanotide is an alpha-melanocyte-stimulating hormone (alpha-MSH) analog that activates melanocortin receptors MC3-R and MC4-R in the central nervous system. Due to its centrally mediated activity, Bremelanotide has potential for the treatment of erectile dysfunction, as well as for possible use in unmet medical needs associated with decreased sexual motivation and loss of libido.

PT-14 is a powerful erection initiator with minimal side effects, a rapid onset of action and a fairly long duration of action. In particular, recent phase II studies confirm that erectile responses are improved with sexual stimulation.  Thanks to its central mechanism of action, PT-141 can act independently or in synergy with PDE-5 inhibitors (Viagra, Cialis) and provide a useful alternative therapy for erectile dysfunction of both organic and psychogenic origin. A randomized, prospective, placebo-controlled study compared ED treatment with Sildenafil. mg intranasal PT-con 141. The combined use of two drugs led to a significant increase in the time to increase base stiffness (>60%) compared to taking Sildenafil alone during a 2.5 monitoring session hours. The drug combination was well tolerated with no significant increase in side effects compared to potted PT of Sildenafil alone.

Effects

• The erectogenic potential of PT-, its tolerability profile and its ability to induce significant erections in patients who do not have an adequate response to a PDE inhibitor (Syslais, Viagra) suggest that PT- may provide a alternative treatment.< /li>
• Increased sexual desire and erection

Side effects

• Nausea
• Heat tray
• Headache

How to use

• The first erection occurs in about 30 minutes. The maximum concentration of the substance in the blood drops within 60 minutes after injection and gradually decreases over 4 hours.
• Combination with other drugs
• For better effect, it can be used with drugs such as Sildenafil and Tadafil.

How to prepare a solution

To prepare an injectable solution, you take a syringe already containing a diluent and inject it into a vial containing a lyophilized powder. Tilt the vial so that the needle touches the wall of the vial. Avoid injecting the diluent directly into the lyophilized powder. The solvent should flow slowly down the wall of the bottle (don’t fill it all at once and take your time). Once all of the diluent has been added to the peptide vial, mix gently (but do not shake or shake the vial) until the lyophilized powder has dissolved and a clear liquid remains. Now the drug is ready for use.

Never mix one peptide with another in the same syringe. This creates the risk that the fragile peptide molecules will be destroyed.

Dosage and administration

Initial dosage

The recommended starting dose is 0.5 mg. This initial dose allows the body to acclimate to the peptides and evaluate the individual response. It is advisable to administer the initial dose under medical supervision to monitor any reactions.

Maintenance dosage

After the initial dose, the maintenance dosage of PT-141 is typically between 1 and 2 mg. This dosage can be administered as needed, based on individual response and desired effect. It is important to stick to the recommended dosing frequency provided by your doctor.

Usage

• The injection can be subcutaneous, intramuscular depending on personal preferences.

Archiving

• The resulting solution can be stored for approximately 21 days in the refrigerator at a temperature of 2-8 degrees Celsius. The storage time increases if the solution was prepared using bacteriostatic water.